Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

NCT04065087 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Canceled by the sponsor

Conditions

Newly Diagnosed Glioblastoma

Interventions

BIOLOGICAL: GX-I7
OTHER: Placebo

Sponsor

Genexine, Inc.